JP2022146830A - Therapeutic agent for retinal detachment - Google Patents
Therapeutic agent for retinal detachment Download PDFInfo
- Publication number
- JP2022146830A JP2022146830A JP2021080662A JP2021080662A JP2022146830A JP 2022146830 A JP2022146830 A JP 2022146830A JP 2021080662 A JP2021080662 A JP 2021080662A JP 2021080662 A JP2021080662 A JP 2021080662A JP 2022146830 A JP2022146830 A JP 2022146830A
- Authority
- JP
- Japan
- Prior art keywords
- retinal detachment
- cause
- therapeutic agent
- agent
- viruses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010038848 Retinal detachment Diseases 0.000 title claims abstract description 20
- 230000004264 retinal detachment Effects 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 title abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 241000700605 Viruses Species 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 230000007850 degeneration Effects 0.000 claims abstract description 5
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 5
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract description 3
- 210000005252 bulbus oculi Anatomy 0.000 claims abstract description 3
- 230000004054 inflammatory process Effects 0.000 claims abstract description 3
- 230000035755 proliferation Effects 0.000 claims abstract description 3
- 229940126585 therapeutic drug Drugs 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- -1 hydrogen ions Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、無膜剥離治療薬に関する。 The present invention relates to filmless exfoliation therapeutic agents.
網膜剥離を根本的に治療する薬がない。 There is no cure for retinal detachment.
網膜剥離治療薬を提供することを目的とする。 An object of the present invention is to provide a therapeutic drug for retinal detachment.
本発明の目的を達成するため、次の構成を採用する。
網膜剥離の治療方法として、変性剤を人体に投与することにより、変性をおこし、網膜剥離の原因である眼球内にできた腫瘍の核酸を壊し増殖を防いだり、他の原因である炎症の原因の身体に侵入した細菌やウイルスのＤＮＡとＲＮＡを壊すことにより増殖を防ぐもの。
網膜剥離の病原体である腫瘍や細菌やウイルスは、核酸を持っている。
核酸とは、ＤＮＡとＲＮＡのことである。
ＤＮＡとＲＮＡは塩基間で水素結合しているが、変性剤を加えてアルカリ性にすると、水素イオンを放出するため変性し、ＤＮＡとＲＮＡの塩基間の水素結合が壊れる。
変性剤を人体に投入して、腫瘍や細菌とウイルスの増殖を防ぐことにより、網膜剥離を治療する。In order to achieve the objects of the present invention, the following configuration is adopted.
As a treatment method for retinal detachment, a denaturing agent is administered to the human body to cause degeneration, destroy the nucleic acid of a tumor that has formed in the eyeball that is the cause of retinal detachment, prevent growth, and cause other causes of inflammation. It prevents proliferation by destroying the DNA and RNA of bacteria and viruses that have invaded the human body.
Tumors, bacteria, and viruses that cause retinal detachment contain nucleic acids.
Nucleic acids refer to DNA and RNA.
DNA and RNA are hydrogen-bonded between bases, but when a denaturing agent is added to make them alkaline, hydrogen ions are released and they are denatured, breaking the hydrogen bond between bases of DNA and RNA.
It treats retinal detachment by injecting denaturing agents into the human body to prevent growth of tumors and bacteria and viruses.
変性剤という網膜剥離の治療薬を人体に投与することにより、網膜剥離を治療する。
代表的な変性剤は、尿素薬がある。Retinal detachment is treated by administering a therapeutic drug for retinal detachment called a degenerative agent to the human body.
A representative denaturant is a urea drug.
変性剤という網膜剥離の治療薬を飲み薬として飲むか、注射により投与する網膜剥離の部分を標的とする変性剤を有効成分とするリポソーム医薬品として、人体に投与する方法もある。
代表的な変性剤は、尿素薬がある。There is also a method of administering a therapeutic agent for retinal detachment called a degenerative agent to the human body as an oral drug or as a liposome drug containing a degenerative agent as an active ingredient that targets the retinal detachment by injection.
A representative denaturant is a urea drug.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021080662A JP2022146830A (en) | 2021-03-22 | 2021-03-22 | Therapeutic agent for retinal detachment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021080662A JP2022146830A (en) | 2021-03-22 | 2021-03-22 | Therapeutic agent for retinal detachment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022146830A true JP2022146830A (en) | 2022-10-05 |
Family
ID=83461696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021080662A Pending JP2022146830A (en) | 2021-03-22 | 2021-03-22 | Therapeutic agent for retinal detachment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022146830A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011088911A (en) * | 1999-03-02 | 2011-05-06 | Numoda Biotechnologies Inc | Agent for intravitreal administration for treating or preventing eye disorder |
| JP2013075848A (en) * | 2011-09-30 | 2013-04-25 | Nippon Menaade Keshohin Kk | Anti-inflammatory agent |
-
2021
- 2021-03-22 JP JP2021080662A patent/JP2022146830A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011088911A (en) * | 1999-03-02 | 2011-05-06 | Numoda Biotechnologies Inc | Agent for intravitreal administration for treating or preventing eye disorder |
| JP2013075848A (en) * | 2011-09-30 | 2013-04-25 | Nippon Menaade Keshohin Kk | Anti-inflammatory agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gaynor et al. | Veterinary applications of pulsed electromagnetic field therapy | |
| EP1991303B1 (en) | Method and device for treating microscopic residual tumors remaining in tissues following surgical resection | |
| US10463690B2 (en) | Method and compositions for treating cancerous tumors | |
| MX2023007609A (en) | Methods of enhancing non-viral gene therapy. | |
| Wang et al. | Role of adenosine kinase inhibitor in adenosine augmentation therapy for epilepsy: a potential novel drug for epilepsy | |
| JP2022146830A (en) | Therapeutic agent for retinal detachment | |
| CN107617106A (en) | A kind of anti-scar preparation of Angiotensin-Converting class | |
| AU2010278687A1 (en) | Chemical method for sexual sterilisation and libido suppression in male mammals | |
| JP2022151437A (en) | Agents for treating retinitis | |
| JP2022140190A (en) | Therapeutic agent for autoimmune diseases | |
| JP2022151439A (en) | Agents for treating rhinitis | |
| JP2022151436A (en) | Agents for treating meningitidis and encephalitis | |
| JP2022151430A (en) | Agents for treating cholecystitis | |
| JP2022151433A (en) | Agents for treating cystitis | |
| JP2022151427A (en) | Esophagitis remedy. | |
| JP2022151431A (en) | A remedy for enteritis. | |
| JP2022124985A (en) | Pneumonia therapeutic drugs | |
| JP2022151429A (en) | Agents for treating pancreatitis | |
| JP2022151432A (en) | Agents for treating myocarditis and pericarditis | |
| JP2022151438A (en) | Agents for treating conchitis and tympanitis | |
| JP2022140194A (en) | Therapeutic agent for connective tissue diseases | |
| JP2022151440A (en) | Agents for treating arthritis | |
| JP2022151428A (en) | Agent for treating nephritis | |
| JP2022151423A (en) | Agents for treating disc herniation | |
| JP2022146828A (en) | Therapeutic agents for gastritis, gastric ulcer, and duodenal ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210817 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220726 |